Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma

Abstract

Insights

Ethanol (EtOH) partially suppresses mTOR signaling and protein translation in diffuse large B-cell lymphoma (DLBCL) cells, unlike complete inhibition by INK128. This differential effect leads to distinct cellular responses and survival outcomes in cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Aberrant mechanistic target of rapamycin (mTOR) kinase signaling is implicated in cancer pathogenesis.
  • Ethanol (EtOH) is known to suppress mTOR signaling non-catalytically, with population studies suggesting a protective effect against hematological malignancies.
  • The precise mechanisms of EtOH's modulation of mTOR activity and its downstream effects in cancer cells remain largely unknown.

Purpose of the Study:

  • To evaluate the effects of EtOH on the mTOR pathway in diffuse large B-cell lymphoma (DLBCL) cells.
  • To compare EtOH's effects with those of the active-site mTOR inhibitor INK128.
  • To analyze the downstream effects of EtOH and INK128 on protein translation via translatome analysis.

Main Methods:

  • Treatment of DLBCL cells with EtOH and INK128.
  • Assessment of mTORC1/2 complex formation and AKT phosphorylation.
  • Cap-dependent translation and global protein synthesis assays.
  • Microarray analysis of polysomal RNA to compare translatome profiles.

Main Results:

  • EtOH suppressed mTORC1 but increased AKT phosphorylation and mTORC2 assembly, while INK128 abrogated AKT phosphorylation.
  • EtOH partially suppressed protein translation and induced stress granules, whereas INK128 strongly inhibited translation and suppressed stress granules.
  • Both agents inhibited cell cycle, proliferation, and autophagy, but only INK128 induced apoptosis; EtOH and INK128 modulated distinct sets of genes involved in cell growth and survival.

Conclusions:

  • EtOH partially inhibits mTOR signaling and protein translation in DLBCL, contrasting with the complete inhibition by INK128.
  • Differential inhibition of mTOR by EtOH and INK128 distinctly modulates the translation of specific mRNA subsets.
  • These distinct modulations lead to differential cellular responses and survival outcomes in DLBCL malignancy.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K